The publication of successful Phase 3 trial results in a reputable journal like the Journal of Clinical Oncology is a significant milestone for Actinium Pharmaceuticals. It demonstrates the efficacy of Iomab-B, which is likely to increase investor confidence and positively impact the stock price. The focus on complete remission and event-free survival are critical endpoints that enhance the drug's potential marketability.